Vetiqure AB

𝐒𝐜𝐚𝐧𝐝𝐢𝐧𝐚𝐯𝐢𝐚𝐧 𝐂𝐡𝐞𝐦𝐨𝐓𝐞𝐜𝐡’𝐬 𝐀𝐧𝐢𝐦𝐚𝐥 𝐂𝐚𝐫𝐞 𝐂𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐬 𝐭𝐨 𝐆𝐫𝐨𝐰! Animal Care is closing 2024 on a high, with strong sales growth driven by the increasing adoption of the vetIQure™ TSE system. Repeat purchases from satisfied customers underline the trust and value our technology brings to veterinary practices. 𝐂𝐄𝐎 𝐌𝐨𝐡𝐚𝐧 𝐅𝐫𝐢𝐜𝐤: "Our expanding presence in the USA and Europe reflects the clinical and economic benefits of TSE technology." We’re looking forward to building on this momentum in 2025! Read the full press release here: https://lnkd.in/ddhPZAd6 Vetiqure AB #VeterinaryCare #Innovation #AnimalCare #vetIQure #Growth #medtech #animalcare #BusinessDevelopment #vettech

We are proud to see Equitom using our Tumor Specific Electroporation (TSE) technology to provide advanced care for horses. It’s inspiring to see innovative solutions improving the lives of these incredible animals. #EquineCare #Innovation #VetiqureTechnology #Equitom

📖 Our Autumn edition of Clinical Connections is out now: ▪️ Oncology case study ▪️ Blood Donor Programme moves ▪️ IMTP patient saved by donors ▪️ Rabbit referrals ➡️ Read online: https://lnkd.in/ezmRBwjS 🔔 Subscribe: https://lnkd.in/eXvfFEAB

𝐕𝐢𝐩𝐞𝐫’𝐬 𝐕𝐢𝐜𝐭𝐨𝐫𝐲 𝐎𝐯𝐞𝐫 𝐇𝐞𝐦𝐚𝐧𝐠𝐢𝐨𝐬𝐚𝐫𝐜𝐨𝐦𝐚 𝐰𝐢𝐭𝐡 𝐓𝐒𝐄 𝐕𝐢𝐩𝐞𝐫’𝐬 𝐉𝐨𝐮𝐫𝐧𝐞𝐲 – Viper, a 7-year-old Dutch Shepherd working with a sheriff’s department, was diagnosed with a high-grade Subcutaneous Hemangiosarcoma. This aggressive cancer posed a risk to his health and active lifestyle. Viper’s veterinarian used vetIQure’s Tumor Specific Electroporation (TSE) technology to provide targeted treatment. 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐏𝐚𝐭𝐡: With TSE, Viper’s veterinarian was able to treat the tumor effectively without compromising surrounding healthy tissue. Viper’s latest checkups confirm no signs of tumor regrowth, allowing him to continue his essential work with full mobility. 𝐎𝐮𝐭𝐜𝐨𝐦𝐞: We’re proud that TSE has helped veterinarians support pets like Viper in maintaining their quality of life. His case illustrates how TSE can be a powerful tool for treating aggressive cancers without impacting a pet’s active role. #vetIQure #innovation #CancerTreatment #VeterinaryOncology #Hemangiosarcoma #VeterinaryMedicine #medtech #TumorElectroporation #veterinarymedicine #veterinary

𝐋𝐞𝐞’𝐬 𝐒𝐮𝐜𝐜𝐞𝐬𝐬 𝐰𝐢𝐭𝐡 𝐍𝐨𝐧-𝐒𝐮𝐫𝐠𝐢𝐜𝐚𝐥 𝐓𝐒𝐄 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐋𝐞𝐞’𝐬 𝐂𝐚𝐬𝐞 – A 9-year-old Labrador was diagnosed with a mast cell tumor located on his eyelid, a difficult area for traditional cancer treatments. Lee’s veterinarian turned to vetiqure’s Tumor Specific Electroporation (TSE) technology as a precise, non-surgical option. 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐏𝐫𝐨𝐜𝐞𝐬𝐬: With just one TSE treatment, the tumor size reduced significantly, making surgery unnecessary. A second treatment completed the process, leaving a minimal pale scar. Lee retained his vision and eye comfort without needing invasive surgery. 𝐎𝐮𝐭𝐜𝐨𝐦𝐞: Thanks to TSE, Lee’s veterinarian achieved a successful outcome with no tumor regrowth, maintaining Lee’s eye health and quality of life. This case highlights how TSE is empowering veterinarians to tackle challenging tumors in sensitive locations. #vetiQure #TSE #VeterinaryOncology #CanineCancer #MastCellTumor #NonInvasiveTreatment #VeterinaryInnovation #innovation #cancertreatment #vettech

A number of new surgery videos have been posted to our Cap City Specialist Surgery Videos site on YouTube (see https://lnkd.in/dsdqW54X), including: - Parathyroidectomy in a dog with primary hyperparathyroidism - Coxofemoral disarticulation in a dog - Thymoma resection via a median sternotomy - Total cystectomy - Wide resection of a soft tissue sarcoma - Total unilateral maxillectomy via a combined approach for a cat with a SCC - Caudal maxillectomy-orbitectomy-palatectomy for a dog with a palatine MLO Dr. Phil Larose did a video on a caudal superficial epigastric axial pattern flap today (which is presently located in our live streams [https://lnkd.in/dFwvBb84] and will soon make its way to our video page), and I have a few live streams happening tomorrow. These include an anal sacculectomy and sublumbar lymph node excision, single-session bilateral mastectomy in a cat, and a wide cutaneous MCT resection in a dog. I hope you are enjoying this resource!

𝐀𝐧𝐠𝐞𝐥’𝐬 𝐉𝐨𝐮𝐫𝐧𝐞𝐲 𝐰𝐢𝐭𝐡 𝐓𝐒𝐄 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐀𝐧𝐠𝐞𝐥’𝐬 𝐒𝐭𝐨𝐫𝐲 – An 11-year-old feline patient diagnosed with Feline Injection Site Sarcoma. Faced with a challenging cancer diagnosis, Angel’s owner wanted to avoid amputation. Fortunately, their veterinarian used vetIQure’s Tumor Specific Electroporation (TSE) technology to provide a less invasive treatment option. 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡: Angel received two TSE treatments in combination with surgery to remove the tumor with minimal risk of regrowth. Over a year later, Angel remains in complete remission with no signs of scarring or recurrence. 𝐎𝐮𝐭𝐜𝐨𝐦𝐞: Angel’s case is a great example of how veterinarians are using TSE technology to treat aggressive cancers effectively while preserving quality of life. We’re proud to support vets in offering treatments that are kinder and less invasive for pets. #vetiQure #TSE #VeterinaryOncology #FelineCancer #PetCancerCare #TumorElectroporation #InnovationInVetMed #innovation #veterinarymedicine #medtech

We had a great time attending the 2024 Veterinary Cancer Society (VCS) Annual Conference! Thank you to everyone who visited our booth and engaged with us at vetiqure. It was a pleasure to share insights and discuss advancements in veterinary oncology with all of you. Check out these four exciting case studies we showcased, highlighting the use of Tumor Specific Electroporation™ (TSE), a groundbreaking technology that improves treatment outcomes for a variety of challenging tumor types in both canine and feline patients: 1. 𝐕𝐢𝐩𝐞𝐫, a 7-year-old Dutch Shepherd, was treated for a high-grade subcutaneous hemangiosarcoma using TSE and remains tumor-free, continuing his active role in the sheriff’s department. 2. 𝐀𝐧𝐠𝐞𝐥, an 11-year-old cat, avoided amputation with the help of TSE in managing a pleomorphic giant cell sarcoma, achieving full remission without tumor recurrence. 3. 𝐓𝐚𝐧𝐧𝐞𝐫, a 5-year-old Rhodesian Ridgeback, underwent TSE treatment for a cutaneous mast cell tumor and has been in complete remission for over a year. 4. 𝐋𝐞𝐞, a 9-year-old Labrador cross, successfully treated for an eyelid mast cell tumor, avoided surgery, and retained normal eye function post-TSE treatment. It was inspiring to share these success stories and exchange knowledge on how technology is advancing veterinary oncology. Looking forward to future collaborations and progress! #VCS2024 #VetOncology #vetIQure #TSE #CancerTreatment #VeterinaryInnovation #innovation #veterinarymedicine #medtech #collaboration

Danny E. Nesrallah and the Vetiqure AB team have just landed in Orlando, Florida! Join us at the VCS Annual Conference 2024, where we’ll present exciting case studies and showcase new posters from a renowned veterinary oncologist. Stay tuned for updates from the event! #vetIQure #VCS2024 #VeterinaryOncology #CaseStudies #Innovation #AnimalHealth #VetConference #OrlandoEvents #veterinarymedicin #medtech

𝐂𝐄𝐎 𝐕𝐢𝐬𝐢𝐭 𝐭𝐨 𝐎𝐮𝐫 𝐍𝐨𝐫𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚𝐧 𝐇𝐞𝐚𝐝𝐪𝐮𝐚𝐫𝐭𝐞𝐫𝐬 Today, our CEO Mohan Frick met with our Head of Business Development North America, Danny Nesrallah, at our North American headquarter in Boca Raton, Florida to prepare for the upcoming VCS Annual Conference in Orlando. We will be showcasing new posters featuring treatments from a well-respected oncologist, which have shown strong results in clinical settings. We welcome all veterinarians attending the conference to visit us and discuss the latest in TSE and explore potential collaborations in veterinary oncology. In addition, our CEO is dedicating a week to exploring the U.S. market, focusing on identifying potential clients and clinics to further expand our business opportunities. Stay tuned for updates and insights into the posters we will be sharing at the event. #Leadership #VeterinaryOncology #BusinessDevelopment #Healthcare #VCS2024 #innovation #Orlando #medtech #veterinaryoncology #animalcare